Re: Felix Seelemeyer, David Pfister, Robert Pappesch, et al. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021
-
Published:2024-04
Issue:2
Volume:7
Page:307
-
ISSN:2588-9311
-
Container-title:European Urology Oncology
-
language:en
-
Short-container-title:European Urology Oncology
Author:
Urabe FumihikoORCID,
Yoshioka Takashi,
Kimura Takahiro
Reference5 articles.
1. Seelemeyer F, Pfister D, Pappesch R, Merkelbach-Bruse S, Paffenholz P, Heidenreich A. Evaluation of a miRNA-371a-3p assay for predicting final histopathology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy for stage IIA/B seminoma or nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021.
2. Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review;Leão;Eur Urol,2021
3. Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study;Dieckmann;J Clin Oncol,2019
4. Standard operating procedures for serum and plasma collection: Early Detection Research Network consensus statement. Standard Operating Procedure Integration Working Group;Tuck;J Proteome Res,2009
5. Development of circulating microRNA-based biomarkers for medical decision-making: a friendly reminder of what should not be done;Lakkisto;Crit Rev Clin Lab Sci,2023